glp-1 receptor agonist and dpp-4 inhibitor combination not recommended inhibitors for type 2 diabetes management combining glp-1 receptor agonist with
Description
10.3390/ph17020199 5 ArdJ.FitchA.FruhS.HermanL
2015 Jan;39(1):187 )
Researchers not involved in the University of Pennsylvania study said it contributes to growing research involving GLP-1 drugs commonly prescribed for weight loss and to treat Type 2 diabetes
GLP-1 receptors have been identified within myocardial tissue and autonomic centres [21,22,23], with murine studies demonstrating effects on heart rate, endothelial function and regulation of the autonomic nervous system [24,25,26]
Byetta (Exenatide) highlights of prescribing information
